Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.47 |
| ▸ | IKBKB | O14920 | 6/20 | 0.40 |
| ▸ | CHUK | O15111 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653478 | 0.86 | KEAP1 (0.41) | PDPK1IKBKBCHUKALDH1A1ATM | |
| SCHEMBL29158222 | 0.85 | CSNK1A1 (0.40) | PDPK1IKBKBCHUKALDH1A1ATM | |
| SCHEMBL4783577 | 0.78 | — | — | |
| SCHEMBL562266 | 0.76 | — | — | |
| SCHEMBL162641 | 0.76 | — | — | |
| SCHEMBL6672416 | 0.76 | — | — | |
| SCHEMBL30884200 | 0.76 | PDPK1 (0.43) | PDPK1IKBKBCHUKALDH1A1ATM | |
| SCHEMBL5609871 | 0.76 | PDPK1 (0.43) | PDPK1IKBKBCHUKALDH1A1ATM | |
| SCHEMBL16043412 | 0.74 | — | — | |
| SCHEMBL849718 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192278-A | Azole bisamide-containing compound and preparation method and application thereof | 江西天宇化工有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-120192278-A | Azole bisamide-containing compound and preparation method and application thereof | 江西天宇化工有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-120192278-A | Azole bisamide-containing compound and preparation method and application thereof | 江西天宇化工有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-120192278-A | Azole bisamide-containing compound and preparation method and application thereof | 江西天宇化工有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| EP-2809669-B1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-9284333-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-03-15 | — | — | US | disclosed |
| EP-2809669-A1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-10 | — | — | EP | disclosed |
| EP-2809669-A1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-10 | — | — | EP | disclosed |
| CN-104169281-A | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI SA | 2014-11-26 | — | — | CN | disclosed |
| CN-104169281-A | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI SA | 2014-11-26 | — | — | CN | disclosed |
| WO-2013113860-A1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013113860-A1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-08-08 | — | — | WO | disclosed |
| US-6239159-B1 | SUBSTRATES FOR POLYMERASE AND TERMINAL TRANSFERASE ENZYMES. CAPABLE OF BASE-PAIRING WITH A NUCLEOTIDE RESIDUE IN A COMPLEMENTARY CHAIN OR BASE STACKING IN THE APPROPRIATE NUCLEIC ACID CHAIN, ADVANTAGE OVER CONVENTIONAL HAPTEN | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 2001-05-29 | — | — | US | disclosed |
| EP-0885235-A1 | NUCLEOSIDE ANALOGUES | Amersham Pharmacia Biotech UK Limited (GB) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997028176-A1 | NUCLEOSIDE ANALOGUES | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | KCNA1, KCNE1, KCNH1 | PDPK1 1890/4885IKBKB 4441/4885CHUK 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.